COMPANY RESEARCHSinocelltech Group Limited
Sinocelltech is a Chinese biopharmaceutical company engaged in developing, manufacturing and commercializing biological medicines. Its research activities include monoclonal antibodies, recombinant proteins and vaccines for diseases with significant medical needs. The corporate website identifies its Shanghai STAR Market listing and describes its research platforms, approved products and manufacturing capabilities. The company has worked across therapeutic as well as preventive biologic development. This directory emphasizes the company's issuer identity and long-term technical capabilities without maintaining a full inventory of changing clinical studies or product indications.
Company at a glance
Corporate information
- Company entity
- Sinocelltech Group Limited
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.sinocelltech.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE STAR: 688520
biologics development
immunology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Sinocelltech is a Chinese biopharmaceutical company engaged in developing, manufacturing and commercializing biological medicines. Its research activities include monoclonal antibodies, recombinant proteins and vaccines for diseases with significant medical needs. The corporate website identifies its Shanghai STAR Market listing and describes its research platforms, approved products and manufacturing capabilities. The company has worked across therapeutic as well as preventive biologic development. This directory emphasizes the company's issuer identity and long-term technical capabilities without maintaining a full inventory of changing clinical studies or product indications.
Business, technology & evidence
- SecuritiesSSE STAR: 688520
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Sinocelltech Group Limited ↗Sinocelltech Group Limited ·
- Official issuer and R&D disclosure · Sinocelltech Group Limited ↗Sinocelltech Group Limited ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.